Based on the analysis results, we further demonstrated that the high-risk IA subgroup was sensitive to drugs related to classical tumor driver pathways, such as the p53 pathway and receptor tyrosine kinase (RTK) pathway (Fig. 5D). This evidence concerns the gene TP53 and neoplasm.